GVHD
Advertisement
The condition is an "underdiagnosed gynecologic comorbidity" that often co-occurs with multiorgan chronic GVHD.
Previous research showed a potential connection between obesity and moderate to severe GVHD post-allogeneic SCT.
Oncology nurses need to be equipped to dispel common myths about smoking.
Learn how oncology nurses can offer education and smoking cessation resources to help patients reduce their risk.
Learn how ACCESS study data is informing patient-centered GVHD care and eliminating the donor access barrier for HSCT trials.
Recent research highlights the need for proactive interventions by oncology nurses.
If patients who smoke understand the pathophysiology, they may be more open to difficult conversations about cessation.
Stephen R. Spellman shares highlights from the results of the ACCESS trial, which was presented at the 2025 Tandem Meetings.
The study evaluated the safety and efficacy of ruxolitinib for treating chronic graft-versus-host disease after allo-HSCT.
Partially hydrolyzed guar gum, a soluble dietary fiber obtained from guar beans, was evaluated due to its butyrate content.
The Lee Symptom Scale for skin sclerosis was informed by patient interviews and feedback.
Patients with cGVHD appreciate the opportunity to connect with other individuals also navigating a cGVHD diagnosis.
Access to a multidisciplinary GVHD clinic with telehealth abilities improved care for patients with acute and chronic GVHD.
Learn how oral dysbiosis correlates with exacerbated cGVHD in patients after receiving hematopoietic cell transplantation.
Novel agents recently approved by the FDA showed promising responses when combined for treating refractory cGVHD.
The study highlights the need for improved patient education and provider communication on early symptoms of cGVHD.
Research presented at ASH 2024 highlighted the importance of absolute monocyte counts after transplant.
Research presented at ASH 2024 showed that adding budesonide didn’t compromise immunologic recovery and transplant ...
A study presented at the 2024 ASH Annual Meeting suggests that a certain test may predict GI issues caused by GVHD.
An expert in pediatric GVHD shares his hopes and projections for the future of GVHD treatment and research.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.